Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cutanea Life Sciences
Malvern, PA, United Statescutanealife.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Cutanea Life Sciences developed dermatology therapeutics including combination and peptide drugs, with omiganan (c. 2011) progressing to phase 3 for rosacea. Marketed products included Aktipak (erythromycin + benzoyl peroxide) for acne and Xepi (ozenoxacin) for impetigo. Company was acquired by Biofrontera in 2019.[2][5][6]
- Therapeutic areas
- Infectious DiseasesDermatology
- Modalities
- PeptidesSmall moleculeSmall molecule + biologic
- Industry
- Biotech
02
Partnerships
MaruhoBiofrontera
Beyond the preview
Go deeper on Cutanea Life Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cutanea Life Sciences.